AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36581881 — intervention group
Group type: EXPERIMENTAL
Intervention: MLP
Number of subjects: 6891
Study 36581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Final ensemble model after transfer learning and ensemble learning
Number of subjects: 6891
Study 36581893 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n=194)
Number of subjects: 373
Study 36581893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=179)
Number of subjects: 373
Study 36581902 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) associated with pain neuroscience education (PNE) and clinical hypnosis (CH)
Number of subjects: 0
Study 36581902 — intervention group
Group type: COMPARATOR
Intervention: PNE, CH, and sham therapy
Number of subjects: 0
Study 36581901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined papillary muscle relocation and ring annuloplasty
Number of subjects: 97
Study 36581914 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 5 fractions of 8 Gy
Number of subjects: 0
Study 36581914 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 36581914 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 0
Study 36581937 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive treatment
Number of subjects: 0
Study 36581937 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 0
Study 36581960 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300
Study 36581960 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 300
Study 36581962 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic lesion on head CT
Number of subjects: 20000
Study 36581962 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant lesion
Number of subjects: 20000
Study 36581983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated regimen of 2.67 Gy for 16 fractions
Number of subjects: 801
Study 36581983 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen of 2 Gy for 25 fractions
Number of subjects: 801
Study 36581996 — intervention group
Group type: EXPERIMENTAL
Intervention: Active irrigation in external ventricular drainage (IRRAflow)
Number of subjects: 58
Study 36581996 — intervention group
Group type: COMPARATOR
Intervention: Passive external ventricular drainage (EVD)
Number of subjects: 58
Study 36582001 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Number of subjects: 216
Study 36582001 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 216
Study 36582001 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-HIFU + EBRT
Number of subjects: 216
Study 36582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade (ICB) immunotherapy
Number of subjects: 41
Study 36582225 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 41
Study 36582243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavrotolimod (5, 10, 12.5, and 18.8 µg/kg)
Number of subjects: 16
Study 36582297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Switch RingFit Adventure (RFA) exergame-based exercise, details on dosage and duration not available.
Number of subjects: 0
Study 36582297 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 36582390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (1 hour per day, 5 days per week for 12 weeks)
Number of subjects: 82
Study 36582390 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (delayed Tai Chi training)
Number of subjects: 82
Study 36582423 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam therapy (PBT)
Number of subjects: 20
Study 36582423 — intervention group
Group type: COMPARATOR
Intervention: Photon beam therapy (SCRT with photons)
Number of subjects: 20
Study 36582659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 232
Study 36582659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 232
Study 36582659 — intervention group
Group type: EXPERIMENTAL
Intervention: Christian Prayer (CP)
Number of subjects: 232
Study 36582659 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (CN)
Number of subjects: 232
Study 36582742 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRP3 variant G-allele carriers
Number of subjects: 1001
Study 36583069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity yoga (HY)
Number of subjects: 30
Study 36583069 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity yoga (MY)
Number of subjects: 30
Study 36583069 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 30
Study 36583171 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg or 300 mg once daily continuously and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity.
Number of subjects: 40
Study 36583171 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus anlotinib
Number of subjects: 40
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine C3dg and sC5b-9-associated C9 neoantigen/creatinine ratios
Number of subjects: 88
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine plasmin(ogen)
Number of subjects: 88
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin
Number of subjects: 88
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane-associated C3dg and C9 neoantigen
Number of subjects: 88
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: C3dg and C9 neoantigen
Number of subjects: 88
Study 36583350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of activated complement
Number of subjects: 88
Study 36583355 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg once daily for 90 days
Number of subjects: 823
Study 36583355 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 15 mg once daily for 90 days
Number of subjects: 823
Study 36583355 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg once daily for 90 days
Number of subjects: 823
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h TTR for SBP (90-140 mmHg)
Number of subjects: 228
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h TTR for DBP (60-90 mmHg)
Number of subjects: 228
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h TTR for MAP
Number of subjects: 228
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in TTR of DBP
Number of subjects: 228
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in TTR of MAP
Number of subjects: 228
Study 36583356 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR of SBP in 130-180 mmHg and 110-160 mmHg ranges
Number of subjects: 228
Study 36583436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device (VCD) implantation
Number of subjects: 1580
Study 36583436 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 1580
Study 36583436 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD implantation
Number of subjects: 1580
Study 36583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene (5 mg daily for chronic treatment; 20 mg for flare-ups for 4 weeks, then 10 mg for ≥8 weeks, weight-adjusted if skeletally immature)
Number of subjects: 97
Study 36583535 — intervention group
Group type: COMPARATOR
Intervention: NHS (natural history study participants, untreated beyond standard of care)
Number of subjects: 97
Study 36583633 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0
Study 36583633 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0
Study 36583633 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 36583633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36583643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalert with patient alerts (Monitor + Alert, N = 25)
Number of subjects: 49
Study 36583643 — intervention group
Group type: COMPARATOR
Intervention: Oxalert without patient alerts (Monitor Only, N = 24)
Number of subjects: 49
Study 36583684 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Feedback intervention
Number of subjects: 120
Study 36583684 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 120
Study 36583806 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increased hypermetabolism in VSS patients in the lingual gyrus and cuneus
Number of subjects: 0
Study 36583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus worsening trajectory (n=166)
Number of subjects: 1252
Study 36583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus worsening trajectory (n=118)
Number of subjects: 1252
Study 36583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral trajectory (n=378)
Number of subjects: 1252
Study 36583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus stable trajectory (n=328)
Number of subjects: 1252
Study 36583920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus stable trajectory (n=262)
Number of subjects: 1252
Study 36583938 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch 7
Number of subjects: 201
Study 36583938 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Fenix 6 Pro
Number of subjects: 201
Study 36583938 — intervention group
Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Number of subjects: 201
Study 36583938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Sense
Number of subjects: 201
Study 36583990 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs manufactured using CliniMACS Cytokine Capture System (CCS)
Number of subjects: 0
Study 36583990 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs manufactured using CliniMACS CCS
Number of subjects: 0
Study 36583990 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs
Number of subjects: 0
Study 36583998 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 4427
Study 36583998 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 4427
Study 36584022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 0
Study 36584027 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavior change intervention delivered via videoconferencing technology by trained PA counsellors
Number of subjects: 0
Study 36584027 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no intervention)
Number of subjects: 0
Study 36584027 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavior change intervention
Number of subjects: 0
Study 36584053 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with ropivacaine 0.75%, 0.35 ml.kg-1
Number of subjects: 102
Study 36584053 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 102
Study 36584053 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 102
Study 36584099 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 712
Study 36584099 — intervention group
Group type: COMPARATOR
Intervention: Nonrecipient group (no favipiravir)
Number of subjects: 712
Study 36584099 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone (not an intervention but a factor)
Number of subjects: 712
Study 36584183 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with HIV (WWH)
Number of subjects: 20
Study 36584183 — intervention group
Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 20
Study 36584183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory monocyte activation among WWH
Number of subjects: 20
Study 36584248 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Lipoic Acid (ALA) 100 mg/d
Number of subjects: 0
Study 36584248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36584579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-growth-factor injection
Number of subjects: 40
Study 36584579 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 40
Study 36584579 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking while reading on a smartphone
Number of subjects: 40
Study 36584579 — intervention group
Group type: COMPARATOR
Intervention: Normal walking without neck pain
Number of subjects: 40
Study 36584711 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D (baseline and first follow up) to predict remission rates at treatment step 1.
Number of subjects: 0
Study 36584711 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 2.
Number of subjects: 0
Study 36584711 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 3.
Number of subjects: 0
Study 36584835 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued treatment early
Number of subjects: 150
Study 36584835 — intervention group
Group type: COMPARATOR
Intervention: Treated intermittently
Number of subjects: 150
Study 36584835 — intervention group
Group type: COMPARATOR
Intervention: Treated continuously
Number of subjects: 150
Study 36585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-off
Number of subjects: 18
Study 36585028 — intervention group
Group type: EXPERIMENTAL
Intervention: In-flight
Number of subjects: 18
Study 36585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Landing
Number of subjects: 18
Study 36585028 — intervention group
Group type: COMPARATOR
Intervention: Take-off to In-flight comparison
Number of subjects: 18
Study 36585028 — intervention group
Group type: COMPARATOR
Intervention: In-flight to Landing comparison
Number of subjects: 18
Study 36585028 — intervention group
Group type: COMPARATOR
Intervention: Take-off to Landing comparison
Number of subjects: 18
Study 36585126 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT parameters
Number of subjects: 230
Study 36585126 — intervention group
Group type: EXPERIMENTAL
Intervention: VF MD
Number of subjects: 230
Study 36585126 — intervention group
Group type: EXPERIMENTAL
Intervention: wiVD
Number of subjects: 230
Study 36585127 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg/mL weekly subcutaneous injections
Number of subjects: 15
Study 36585130 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (starting at 2.5 mg two times per day, titrating up to a maximum dose of 10 mg two times per day)
Number of subjects: 106
Study 36585130 — intervention group
Group type: COMPARATOR
Intervention: Standard care (high-dose anthracycline-based chemotherapy)
Number of subjects: 106
Study 36585130 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 106
Study 36585130 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 106
Study 36585131 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 870
Study 36585131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 36585135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis training for 10 minutes/day over 8 weeks
Number of subjects: 60
Study 36585135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis training
Number of subjects: 60
Study 36585135 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study 36585137 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine
Number of subjects: 6943
Study 36585139 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily synbiotic intervention (combining human milk oligosaccharide and probiotic)
Number of subjects: 144
Study 36585139 — intervention group
Group type: COMPARATOR
Intervention: Identical-looking placebo
Number of subjects: 144
Study 36585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep measurements and CSF-orexin-A
Number of subjects: 200
Study 36585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in AD and/or glial activation markers
Number of subjects: 200
Study 36585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 200
Study 36585144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemonitoring programme
Number of subjects: 50
Study 36585147 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF intervention (behaviour change modules and small-quantity lipid-based nutrient supplements from 6 to 12 months of age)
Number of subjects: 192
Study 36585147 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF-plus intervention (IYCF components plus powdered NUA-45 biofortified sugar beans, whole egg powder, moringa leaf powder, and provitamin A maize)
Number of subjects: 192
Study 36585147 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF-plus intervention
Number of subjects: 192
Study 36585153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement during index operation
Number of subjects: 120
Study 36585153 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires developed using a 5-point Likert scale
Number of subjects: 120
Study 36585153 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 120
Study 36585217 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + MTX
Number of subjects: 752
Study 36585217 — intervention group
Group type: COMPARATOR
Intervention: Abatacept placebo + MTX
Number of subjects: 752
Study 36585408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.1 mg/day) plus oral micronized progesterone (200 mg/day as 100 mg twice daily)
Number of subjects: 28
Study 36585408 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 28
Study 36585452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ricolinostat plus nab-paclitaxel
Number of subjects: 3000
Study 36585491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET)
Number of subjects: 31
Study 36585491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 31
Study 36585491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET) and Placebo (PLC)
Number of subjects: 31
Study 36585494 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB + Exercise Training (RYGB + ET)
Number of subjects: 30
Study 36585494 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 30
Study 36585602 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 36585602 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0
Study 36585602 — intervention group
Group type: EXPERIMENTAL
Intervention: eDaily by PsABIOnd substudy
Number of subjects: 0
Study 36585602 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable and digital technologies
Number of subjects: 0
Study 36585602 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 36585602 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety data collection
Number of subjects: 0
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotherapy
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 77 years
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score ≤ 9
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Severity Score (ISS) ≥ 25
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall GOSE score at 3 months
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate at 3 months
Number of subjects: 349
Study 36585608 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal or withholding of life-sustaining therapies
Number of subjects: 349
Study 36585629 — intervention group
Group type: COMPARATOR
Intervention: Postoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 88
Study 36585629 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 88
Study 36585664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride (NSF)
Number of subjects: 50
Study 36585664 — intervention group
Group type: COMPARATOR
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 50
Study 36585676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Enhancing and Motivating System for Hip (exoskeleton) used in twelve 30-min sessions
Number of subjects: 12
Study 36585676 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise programs
Number of subjects: 12
Study 36585673 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 4423
Study 36585673 — intervention group
Group type: COMPARATOR
Intervention: Non-institutional delivery
Number of subjects: 4423
Study 36585700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) from ICI responding donor
Number of subjects: 24
Study 36585700 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplantation (FMT) from ICI nonresponding donor
Number of subjects: 24
Study 36585700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 24
Study 36585748 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week telehealth exercise program based on the Mann Method
Number of subjects: 18
Study 36585933 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy for fibromyalgia (10 weeks)
Number of subjects: 140
Study 36585933 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 140